Skip to Main Content

Author Details

John D Gordan
Quantitative Biosciences Institute (QBI), University of California San Francisco
1996
58
34
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36692000Oncogenic PKA signaling increases c-MYC protein expression through multiple targetable mechanisms.Elife2023
37425703Recruitment of BAG2 to DNAJ-PKAc scaffolds promotes cell survival and resistance to drug-induced apoptosis in fibrolamellar carcinoma.bioRxiv2023
37402062New Opportunities to Individualize Frontline Therapy in Advanced Stages of Hepatocellular Carcinoma.Drugs2023
36959495Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.NPJ Precis Oncol2023
35087237Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1.Oncogene2022
35525550Methods to assess small molecule allosteric modulators of the STRAD pseudokinase.Methods Enzymol2022
35420673EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion-Positive Cholangiocarcinoma.Cancer Discov2022
35190728A framework for fibrolamellar carcinoma research and clinical trials.Nat Rev Gastroenterol Hepatol2022
34591612A protein interaction landscape of breast cancer.Science2021
33561166Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma.PLoS Comput Biol2021
34950179Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling.Liver Cancer2021
32531271Unbiased Proteomic Profiling Uncovers a Targetable GNAS/PKA/PP2A Axis in Small Cell Lung Cancer Stem Cells.Cancer Cell2020
33197225Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.J Clin Oncol2020
32154962Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.Oncologist2020
32400000A Multicenter Randomized Three-Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.Oncologist2020
32226615Checkpoint Inhibitors for the Treatment of Advanced Hepatocellular Carcinoma.Clin Liver Dis (Hoboken)2020
30643286Translation control of the immune checkpoint in cancer and its therapeutic targeting.Nat Med2019
30084835Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.Clin Cancer Res2019
31195063Loss of Fbxw7 synergizes with activated Akt signaling to promote c-Myc dependent cholangiocarcinogenesis.J Hepatol2019
31478838A single H/ACA small nucleolar RNA mediates tumor suppression downstream of oncogenic RAS.Elife2019
30741922MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment.Cell Death Dis2019
31154669Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series.Cancer2019
30951568Road map for fibrolamellar carcinoma: progress and goals of a diversified approach.J Hepatocell Carcinoma2019
31138768KRAS<sup>G12C</sup> inhibition produces a driver-limited state revealing collateral dependencies.Sci Signal2019
30390071Overexpression-mediated activation of MET in the Golgi promotes HER3/ERBB3 phosphorylation.Oncogene2019
29348467Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model.Cell Death Dis2018
29942081Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer.Nat Chem Biol2018
29545603Notch2 controls hepatocyte-derived cholangiocarcinoma formation in mice.Oncogene2018
29622700Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in <i>BRCA1-</i>Mutant Cholangiocarcinoma Harboring a Novel <i>YWHAZ-BRAF</i> Fusion.Oncologist2018
27940637An Optimized Chromatographic Strategy for Multiplexing In Parallel Reaction Monitoring Mass Spectrometry: Insights from Quantitation of Activated Kinases.Mol Cell Proteomics2017
28869755Sampling strategies to capture single-cell heterogeneity.Nat Methods2017
28733220Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice.J Hepatol2017
27231123Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.Cancer Discov2016
27364904Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib.Mol Cancer Ther2016
25501949Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map.Cancer Discov2015
26134322Identification of Chemical Inhibitors of β-Catenin-Driven Liver Tumorigenesis in Zebrafish.PLoS Genet2015
25127139Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.Cell Rep2014
22094876Integrative genomic analyses of sporadic clear cell renal cell carcinoma define disease subtypes and potential new therapeutic targets.Cancer Res2012
21245436"And what other medications are you taking?".J Clin Oncol2011
19448672Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma.Oncogene2009
19706526HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses.Proc Natl Acad Sci U S A2009
18430730Hypoxia-mediated selective mRNA translation by an internal ribosome entry site-independent mechanism.J Biol Chem2008
19061835HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma.Cancer Cell2008
17208433Hypoxia-inducible factors: central regulators of the tumor phenotype.Curr Opin Genet Dev2007
17692803HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation.Cancer Cell2007
17437992The transcription factor HIF-1alpha plays a critical role in the growth factor-dependent regulation of both aerobic and anaerobic glycolysis.Genes Dev2007
17418410HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity.Cancer Cell2007
16510872HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth.Genes Dev2006
16893887Ribosomal stress couples the unfolded protein response to p53-dependent cell cycle arrest.J Biol Chem2006
15477347ADAP-SLP-76 binding differentially regulates supramolecular activation cluster (SMAC) formation relative to T cell-APC conjugation.J Exp Med2004
  • 1 - 50 of 58

Recommended Authors

Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year 2013
Number of shared co-authors 0
Johannes C van der Mijn
New York Presbyterian Hospital
Career Start Year 2012
Number of shared co-authors 0
Cristina Ivan
The University of Texas MD Anderson Cancer Center
Career Start Year 2010
Number of shared co-authors 0
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year 2010
Number of shared co-authors 0
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year 2010
Number of shared co-authors 0
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year 2009
Number of shared co-authors 0
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 3
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year 2006
Number of shared co-authors 0
Tuan Zea Tan
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year 2005
Number of shared co-authors 0
Kris C Wood
Duke University
Career Start Year 2005
Number of shared co-authors 0
Kurt W Fisher
University of Nebraska Medical Center
Career Start Year 2004
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 2
Xiaohu Zhang
National Center for Advancing Translational Sciences
Career Start Year 2003
Number of shared co-authors 2
Elena Ivanova
Dana-Farber Cancer Institute
Career Start Year 2003
Number of shared co-authors 3
Lixia Diao
The University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 5
Habib Hamidi
Genentech Inc.
Career Start Year 2002
Number of shared co-authors 0
Christopher D Willey
University of Alabama at Birmingham
Career Start Year 2000
Number of shared co-authors 0
Krister Wennerberg
University of Copenhagen
Career Start Year 1994
Number of shared co-authors 3
James J Hsieh
Washington University
Career Start Year 1994
Number of shared co-authors 0
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 6
E Alejandro Sweet-Cordero
University of California San Francisco
Career Start Year 1989
Number of shared co-authors 6
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 9
Wei Zhang
The University of Texas MD Anderson Cancer Center
Career Start Year 1988
Number of shared co-authors 0
Enzo Medico
Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO) - IRCCS
Career Start Year 1988
Number of shared co-authors 2
Daniel S Peeper
Netherlands Cancer Institute
Career Start Year 1987
Number of shared co-authors 7
William C Hahn
Broad Institute of MIT and Harvard, USA Dana-Farber Cancer Institute
Career Start Year 1987
Number of shared co-authors 11
John A Copland
Mayo Clinic Jacksonville
Career Start Year 1982
Number of shared co-authors 0
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year 1979
Number of shared co-authors 5
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Career Start Year 1976
Number of shared co-authors 19
Antonio Jimeno
University of Colorado School of Medicine
Career Start Year 1974
Number of shared co-authors 6

Collaborators

Mareike Simon
Abramson Family Cancer Research Institute, Perelman School of Medicine
Co-authored papers 10
Kevan M Shokat
University of California San Francisco
Co-authored papers 9
Rebecca S Levin
Howard Hughes Medical Institute, University of California San Francisco
Co-authored papers 7
James T Webber
Broad Institute of Harvard and MIT
Co-authored papers 6
Sourav Bandyopadhyay
University of California San Francisco
Co-authored papers 4
Danielle L Swaney
J. David Gladstone Institutes
Co-authored papers 4
Huat Chye Lim
Quantitative Biosciences Institute (QBI), University of California San Francisco
Co-authored papers 4
Nabeel Bardeesy
Massachusetts General Hospital
Co-authored papers 4
Nevan J Krogan (CM4AI)
University of California San Francisco
Co-authored papers 4
Yao-Tseng Chen
From Population Health Services (Chen)
Co-authored papers 3
Lloyd J Old
Ludwig Institute for Cancer Research
Co-authored papers 3
John Alan Diehl
Case Western Reserve University School of Medicine
Co-authored papers 3
Phuong Vu
Harvard Medical School
Co-authored papers 3
Spencer C Behr
University of California san francisco
Co-authored papers 3
Katherine L Nathanson
Perelman School of Medicine, University of Pennsylvania, USA Abramson Cancer Center
Co-authored papers 3
Andrei Goga
University of California San Francisco
Co-authored papers 3
John D Scott
University of Washington
Co-authored papers 2
Praveen Sethupathy
Cornell University
Co-authored papers 2
Alma L Burlingame
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
Mehdi Bouhaddou
J. David Gladstone Institutes
Co-authored papers 2
Frank McCormick
Frederick National Laboratory for Cancer Research
Co-authored papers 2
Wendy Kimryn Rathmell
Co-authored papers 2
Alan Ashworth
UCSF Helen Diller Family Comprehensive Cancer Center
Co-authored papers 2
Kimberly J Riehle
University of Washington
Co-authored papers 2
Heidi L Kenerson
University of Washington
Co-authored papers 2
Julien Sage
Department of Pediatrics Stanford University Stanford California USA.
Co-authored papers 2
Davide Ruggero
University of California San Francisco
Co-authored papers 2
Cyril H Benes
Co-authored papers 2
Jessica A Bertout
Fred Hutchinson Cancer Research Center
Co-authored papers 2
Atul J Butte
Bakar Computational Health Sciences Institute, University of California san francisco
Co-authored papers 1
Release 1.2